RaySearch initiates IMRT European trial to treat rectal cancer

RaySearch Laboratories AB (STO:RAYB) announces that the first patient in Europe has been treated with a treatment plan created with RaySearch's treatment planning system RayStation®. The treatment was carried out at RISO, the Radiotherapeutic Institute in Deventer, the Netherlands. RISO is a public independent radiotherapeutic institute offering radiotherapy for multiple hospitals in the region. The patient is being treated for rectal cancer using Intensity Modulated Radiation Therapy (IMRT) and the treatments are being delivered on an Elekta linear accelerator.

"RayStation® is an entirely new system with a lot of interesting features and a modern workflow. We have now validated the system thoroughly and are very happy with the accuracy and the quality of the plans generated. The system is fast and easy to use and gives us the possibility to create high quality IMRT plans", says Rik Westendorp, medical physicist at RISO.

"The team at RISO is very competent and we are proud that we live up to their quality demands. Earlier this fall the first treatment was carried out in the US and now we pass the next important milestone when the system is used clinically in Europe as well. During the year we have built up a European sales and service organization so we look forward to help RISO and other European clinics as they work hard every day to give cancer patients the best treatments possible", says Johan Löf, CEO of RaySearch.